The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent.
D000818:Animals; D000978:Antiparkinson Agents; D001058:Apomorphine / Q000494:pharmacology; D003024:Clozapine / Q000494:pharmacology; D004347:Drug Interactions; D004639:Emetics; D004873:Ergolines / Q000494:pharmacology*; D006168:Guinea Pigs; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D010479:Pergolide; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D019805:alpha-Methyltyrosine
D000978:Antiparkinson Agents; D004639:Emetics; D004873:Ergolines; D006892:Hydroxydopamines; D008781:Methyltyrosines; D010479:Pergolide; D019805:alpha-Methyltyrosine; D003024:Clozapine; D006220:Haloperidol; D001058:Apomorphine